Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Rituximab in Progressive MS with LME
NCT02253264Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Nov 2014
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Johns Hopkins University. Primary endpoint: Number of serious adverse events at 1 year. Started Nov 2014; status: completed.
02
Drugs
rituximab
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT02253264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253264.